Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™

NCT01358825 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01358825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01358825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
May 30, 2011
Completion date
July 15, 2011
Enrollment
58 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, diphtheria-tetanus-apertussis-poliomyelitis-haemophilus influenzae type b vaccines, haemophilus influenzae type b, hepatitis b, poliomyelitis, tetanus